Trials / Recruiting
RecruitingNCT07262762
Spartina® (Tirzepatide) Effectiveness and Safety Evaluation
A Post-marketing Real-world Study for Evaluating Effectiveness and Safety of Spartina® (Tirzepatide Manufactured by CinnaGen) in Patients With Obesity and Overweight
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 175 (estimated)
- Sponsor
- Cinnagen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight? 2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight? In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)
Conditions
Timeline
- Start date
- 2025-11-11
- Primary completion
- 2025-12-01
- Completion
- 2026-04-01
- First posted
- 2025-12-04
- Last updated
- 2025-12-16
Locations
14 sites across 1 country: Iran
Source: ClinicalTrials.gov record NCT07262762. Inclusion in this directory is not an endorsement.